NCT06221358 Pharmacogenomics of Stimulant Treatment Response
| NCT ID | NCT06221358 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Attention-Deficit/ Hyperactivity Disorder (ADHD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2028-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2024-04-01 with a primary completion date of 2028-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).
Eligibility Criteria
Inclusion Criteria: Patients will be eligible for participation if all the following are true. * Aged 6 - 24 years. * Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba). * Primary diagnosis of ADHD (all types). * Starting Methylphenidate (excluding immediate release forms) treatment. Exclusion Criteria: Patients will be excluded from participation if any of the following are true. * Co-occurring psychotic, bipolar or eating disorders. * Significant risk of suicide. * An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders. * Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use. * Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study * History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.
Contact & Investigator
Chad Bousman, MPH, PhD
PRINCIPAL INVESTIGATOR
University of Calgary
Frequently Asked Questions
Who can join the NCT06221358 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 24 Years, studying Attention-Deficit/ Hyperactivity Disorder (ADHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06221358 currently recruiting?
Yes, NCT06221358 is actively recruiting participants. Contact the research team at sam.siu@ucalgary.ca for enrollment information.
Where is the NCT06221358 trial being conducted?
This trial is being conducted at Calgary, Canada.
Who is sponsoring the NCT06221358 clinical trial?
NCT06221358 is sponsored by University of Calgary. The principal investigator is Chad Bousman, MPH, PhD at University of Calgary. The trial plans to enroll 400 participants.